SpyGlass Pharma Buys IOL Manufacturer AVS for $13M, Securing Supply for Phase 3 Trials
SGP sits 52% above its 52-week low of $17.06.
Summary
SpyGlass Pharma acquired Advanced Vision Science (AVS) from Santen Holdings US, Inc., a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd., for approximately $13 million in cash, subject to customary post-closing adjustments, closing on October 1, 2026. The deal secures the manufacturer that currently supplies the IOL used in SpyGlass's two Phase 3 registrational trials for the BIM-IOL System and gives SpyGlass ownership of AVS's FDA-registered, ISO 13485-certified manufacturing facility, which is also registered by the Japanese Ministry of Health, Labour and Welfare, and its glistening-free hydrophobic acrylic lens material, licensed to Bausch + Lomb for the enVista IOL line including line-extensions and marketing in the rest of the world. AVS will continue as exclusive manufacturer and supplier of several IOL types to Santen for commercialization in Japan, including products under the Eternity brand, and Santen Pharmaceutical Co., Ltd. was granted an exclusive right to sell such products in Japan, providing SpyGlass with a revenue stream and manufacturing scale. The acquisition is strategically important because it removes supply-chain risk for the pivotal trials and positions the company to expand into premium IOLs (toric, extended depth-of-focus) that could fit its drug delivery pads. The $13 million price is modest relative to SpyGlass's $870 million market cap and cash runway through 2028, so the deal is not dilutive. This follows the August 10-Q that disclosed a $19.9 million Q2 loss and an unremediated material weakness in financial controls, but the acquisition itself is a positive operational step. Watch for updates on Phase 3 trial enrollment and any FDA interactions regarding the BIM-IOL System.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The acquisition closed on October 1, 2026, with SpyGlass paying $13 million in cash, subject to customary post-closing adjustments.
- Deal Terms — Seller was Santen Holdings US, Inc., a California corporation. Santen Pharmaceutical Co., Ltd. guaranteed the seller's obligations under the purchase agreement, including indemnification obligations. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd.
- Licensing and Supply — AVS and Santen entered into cross license agreements. AVS will continue to manufacture and supply Eternity brand IOLs to Santen, with Santen granted exclusive right to sell them in Japan. Bausch + Lomb's license includes line-extensions and marketing in the rest of the world.
- Facility Registration — AVS's facility is registered by the Japanese Ministry of Health, Labour and Welfare.
- Advisors — Gitkin & Co. served as financial advisor to SpyGlass Pharma; MTS Health Partners, L.P. served as financial advisor to Santen.
- Customer Support — SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies.
All 10 details
- Seller of Advanced Vision Science (AVS) was Santen Holdings US, Inc., a California corporation.
- Santen Pharmaceutical Co., Ltd., a Japanese company, guaranteed Seller's obligations under the Purchase Agreement, including indemnification obligations.
- AVS and Santen Pharmaceutical Co., Ltd. entered into cross license agreements: AVS granted Parent a non-exclusive, non-sublicensable license under certain AVS intellectual property, and Parent granted AVS a non-exclusive license under certain Parent intellectual property.
- AVS will continue to manufacture and supply intraocular lens products under the Eternity brand to Santen Pharmaceutical Co., Ltd., and Parent was granted an exclusive right to sell such products in Japan.
- AVS's facility is registered by the Japanese Ministry of Health, Labour and Welfare.
- Gitkin & Co. served as financial advisor to SpyGlass Pharma.
- MTS Health Partners, L.P. served as financial advisor to Santen.
- SpyGlass Pharma intends to continue supporting AVS customers and licensees utilizing their proprietary IOL material technology, such as Santen, Bausch + Lomb, and other global IOL companies.
- AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd.
- Bausch + Lomb's license for AVS lens material includes line-extensions and marketing in the rest of the world.
At the time of this announcement, SGP was trading at $26.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $869.6M. The 52-week trading range was $17.06 to $30.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.